Goaweigh wrote: Interesting read on the science but the most relevant aspect of ONC to ATE is that it's listed on NAS and today it's done volume of close to 11,000,000 shares after receiving it's first buy recommendation from HC Wainright who has given it a target price of US $ 15.00
Now didn't we just see a rumour that maybe we may be listing NAS soon and possibly being sponsored by none other than HC Wainright !
Can you imagine what would happen if we did 11,000,000 volume !
Shitzki is all I can say.
You were absolutely correct Goaweigh in saying that ATE would hook up with a US investment bank. Sorry....in my previous reponse to your post I didn't appreciate that this is what you meant by "sponsor".
I owned ONC when it uplisted to Nasdaq. Bought it right after its initial trial results. They were stunning..doubled the mean survival time in metastatic breast cancer patients.
Unfortunately, ONC faltered after the initial pop following uplisting. It has since recovered, partly due to its Chinese partner. I think the problem was that it moved too soon, uplisted without first doing the necessary groundwork, and snagging a partner with deep pockets. It is still a good story.
I recall Dan saying last spring/summer that Antibe had been invited to join Nasdaq, that he had hired a US law firm to complete the paperwork, and was waiting for the right time to strike. Getting to Nasdaq is the easy part. Sustaining SP and institutional investor interest after is more challenging.
Dan said during BioPub that he is still working the "buy side" of the US capital markets, that is, the institutional investors. I'm confident that once he pulls the trigger, they will be onboard, and the SP will continue its momentum. He is doing this exactly the right way, in my view.
askretka wrote:
Company has been working on a virus therapies to kill cancer for about 20 years. It may be all coming together. I never hijack boards like this but this may be a real breakthrough in cancer treatment. 15$ new target today. This might be just the beginning. I'm also an ATE Shareholders